Nothing but NET: a review of norepinephrine transporter expression and efficacy of 131I-mIBG therapy.
Pediatr Blood Cancer
; 62(1): 5-11, 2015 Jan.
Article
en En
| MEDLINE
| ID: mdl-25175627
Neuroblastoma is unique amongst common pediatric cancers for its expression of the norepinephrine transporter (NET), enabling tumor-selective imaging and therapy with radioactive analogues of norepinephrine. The majority of neuroblastoma tumors are avid for (123)I-metaiodobenzaguanidine (mIBG) on imaging, yet the therapeutic response to (131) I-mIBG is only 30% in clinical trials, and off-target effects cause short- and long-term morbidity. We review the contemporary understanding of the tumor-selective uptake, retention, and efflux of meta-iodobenzylguanidine (mIBG) and strategies currently in development for improving its efficacy. Combination treatment strategies aimed at enhancing NET are likely necessary to reach the full potential of (131)I-mIBG therapy.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Radiofármacos
/
3-Yodobencilguanidina
/
Proteínas de Transporte de Noradrenalina a través de la Membrana Plasmática
/
Radioisótopos de Yodo
/
Neuroblastoma
Tipo de estudio:
Prognostic_studies
Límite:
Humans
Idioma:
En
Revista:
Pediatr Blood Cancer
Asunto de la revista:
HEMATOLOGIA
/
NEOPLASIAS
/
PEDIATRIA
Año:
2015
Tipo del documento:
Article
Pais de publicación:
Estados Unidos